TERN
NASDAQTerns Pharmaceuticals Inc.
Price$52.97+18.77 (+54.91%)
2026-01-292026-05-04
News · 26 weeks76-97%
2025-12-142026-06-07
Mix5490d
- SEC Filings22(41%)
- Other19(35%)
- Insider11(20%)
- Analyst1(2%)
- M&A1(2%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form 15-12G filed by Terns Pharmaceuticals Inc.15-12G - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form EFFECT filed by Terns Pharmaceuticals Inc.EFFECT - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- INSIDERSEC Form 4 filed by Director Azelby Robert to satisfy tax liability4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERSEC Form 4 filed by Director Turner Heather D (tax withholding)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERSEC Form 4 filed by Director Tripuraneni Radhika (tax liability)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERSEC Form 4 filed by Director Quigley Jill M. to satisfy withholding obligation4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERSEC Form 4 filed by Director Kindler Jeffrey B (tax withholding)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERSEC Form 4 filed by Director Fellows David A (withholding obligation)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERChief Medical Officer Kuriakose Emil returned $4,343,509 worth of shares to the company (81,953 units at $53.00), closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERChief Financial Officer Gengos Andrew returned $3,643,750 worth of shares to the company (68,750 units at $53.00), closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- INSIDERChief Executive Officer Burroughs Amy L. returned $7,950,000 worth of shares to the company (150,000 units at $53.00), closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form S-8 POS filed by Terns Pharmaceuticals Inc.S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form POS AM filed by Terns Pharmaceuticals Inc.POS AM - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form POSASR filed by Terns Pharmaceuticals Inc.POSASR - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
TERN FAQ
7 questionsWhat does Terns Pharmaceuticals Inc. do?
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced...Where does TERN stock trade?
Terns Pharmaceuticals Inc. (TERN) is listed on NASDAQ.What sector and industry is TERN in?
Terns Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Terns Pharmaceuticals Inc. go public?
Terns Pharmaceuticals Inc. (TERN) completed its IPO in 2021.What are analysts saying about TERN?
Terns Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-03-25. Recent price targets range from $1500.00 to $2000.00.What companies are similar to TERN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TERN side-by-side with any of them on Quantisnow.How can I track TERN on Quantisnow?
Quantisnow aggregates Terns Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TERN to receive live email and push alerts on every new disclosure.